posted
DNAPrint Genomics, Inc. Has Licensed a Diabetes Diagnostic Test Developed by Dr. Jose Halperin at Harvard Medical School Market Wire
SARASOTA, FL -- (MARKET WIRE) -- 01/26/06 -- DNAPrint Genomics, Inc. (OTC BB: DNAG) today announced that the Company and Harvard University have entered into a sponsored research and a field-exclusive licensing agreement. Under the agreement, DNAPrint Genomics, Inc. will sponsor further development in the Laboratory for Translational Research (LTR) at Harvard Medical School of a diagnostic test devised in the Laboratory to target early identification of the population at risk of developing vascular diabetic complications. The Company also will conduct work directed toward its eventual commercialization of the test.
Diabetes is the number one cause of renal transplants, blindness and leg amputations. These are all vascular (blood vessel) complications of diabetes and are the most serious and burdensome effects of the disease for diabetic patients. Treatment of these complications of diabetes consumes 10-15% of the overall US health budget. Therefore, early detection of the diabetic population at risk is a major public health priority as set out by the National Heart Lung and Kidney Institute of the National Institutes of Health in the 1990s. Dr. Jose Halperin, head of the LTR, and members of his research group discovered that a molecule -- called CD59 -- which is a regulator of the complement system, appears to be a key player in how small blood vessels are damaged during the spikes in blood glucose levels that are common in diabetic individuals. Continuous damage to these microvessels is the underlying cause of the kidney, nerve and heart disease that more than 60% of diabetic patients suffer over a lifetime. This discovery of a molecule that is a hallmark of such vessel damage will enable DNAPrint Genomics, Inc. to develop a test to identify even very early stages of microvascular complications.
"Unfortunately, by the time patients are diagnosed with a major complication of diabetes, it may be too late for effective therapy by most available medications and changes in life style," said Dr. Hector Gomez, Chairman and Chief Medical Officer of DNAPrint Genomics, Inc. and the newly formed DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary of DNAPrint Genomics, Inc. This collaboration will further the development of new diagnostic tests that will help physicians and healthcare providers re-direct predisposed patients to healthier lifestyle changes and perhaps even some day, medications to help slow down or prevent the onset of vascular diabetic complications.
"This well advanced technology licensed by DNAPrint Genomics Inc. was developed with support from the National Institutes of Health, which funded much of the early discovery work. We are pleased to have the opportunity to sponsor research that will further develop and eventually commercialize this important diagnostic test that could significantly improve the management of diabetes," said Richard Gabriel, CEO and President of DNAPrint Genomics, Inc
-------------------- Veni Vidi Vici Posts: 529 | From: CA | Registered: Jan 2005
| IP: Logged |
posted
I've played DNAG before. I was hoping it would get a little lower before I got back in. Looks like a good base of bids at .02. Anybody getting in here?
Posts: 344 | From: Berkeley, CA | Registered: Sep 2005
| IP: Logged |
posted
DNAPrint Genomics' Ancestry Test Capabilities Noted in Newsweek Cover Story 2/3/2006
SARASOTA, FL, Feb 03, 2006 (MARKET WIRE via COMTEX) -- DNAPrint Genomics, Inc. (OTC BB: DNAG) today announced that the Company's AncestrybyDNA(TM) technology was cited in the cover story of this week's edition of Newsweek magazine in an article focusing on the growing use of DNA testing to understand family lineage and to answer questions about ancestry.
The magazine's cover for the edition dated February 6 featured the headline "Genes & Family/What Science Can Tell You About Your History And Your Health." The story on the inside was headlined "DNA Testing: In Our Blood," and went on to say that "History lives in our genes. The DNA in each of our cells not only dictates the color of our eyes, it also contains the footprints of our ancestors." The article also mentioned that DNAPrint Genomics specializes in DNA technology for determining a person's ancestry.
Newsweek focused on the growing popularity of DNA testing and how it is giving families surprising glimpses into their past. The author of the article, Claudia Kalb, who was assisted by contributing editor Karen Springen, took the AncestryByDNA(TM) tests offered by DNAPrint Genomics. After receiving the results of the tests, they expressed to DNAPrint Genomics their surprise about details of their ancestry that they did not expect.
The article also mentions Debra Anne Royer, a client of DNAPrint's Trace Genetics subsidiary, who discovered that her maternal ancestry was Native American, providing her important and satisfying knowledge since she was an adopted child. She had always wondered about her background because she often was asked if she were Iranian or Cambodian due to her darker skin and nose characteristics. Newsweek journalists interviewed three other clients of DNAPrint and its Trace Genetics subsidiary, all of whom expressed surprise at their newly founded knowledge about their ancestry.
The article noted that Trace Genetics has a large database of Native American DNA samples. Following publication of the article, DNA Print President and Chief Executive Office Richard Gabriel explained in a statement how this process works. "Native American individuals belong to one of five major maternal lineages or haplogroups, A, B, C, D or X," he explained. "If Trace Genetics' Worldwide Ancestry-Mito test reveals that an individual belongs to one of the five Native American lineages, then we can run a Native American Mito Upgrade. The Mito Upgrade compares the client's mtDNA sequence against the Company's extensive Native American mtDNA database to identify geographic and tribal matches within the Americas."
Mr. Gabriel noted that there is no guarantee of a tribal match, but DNAPrint provides individuals information about whether their DNA is similar to those who claim to have tribal associations. "Having the DNA match does not prove that the client belongs to that tribe; it simply suggests the customer shares a distant common ancestor with individuals in the matched tribe and possibly non-sampled neighboring tribes," he said.
-------------------- Trading is a blast!! Posts: 4921 | From: Rhode Island | Registered: May 2005
| IP: Logged |
posted
DNAG: Among last 10 trades - 8 buys vs. 2 sales. The MMs have just completed the collecting phase. They will raise the pps for a profit. Watch it.
Posts: 3228 | From: Michigan | Registered: Aug 2005
| IP: Logged |
posted
DNAPrint Genomics President Richard Gabriel Discusses Genomics Technology During Interview on National Public Radio
SARASOTA, Fla., April 18, 2006 (PRIMEZONE) -- DNAPrint Genomics, Inc. (OTCBB:DNAG) today announced that President and Chief Executive Officer Richard Gabriel discussed a broad range of issues relating to the Company's complex genomics classification technology in an interview with National Public Radio on Monday, April 17th.
In an interview with Robin Young on the "Here & Now" program facilitated by Boston radio station WBUR, Mr. Gabriel discussed the Company's applications for DNA testing to determine family heritage, law enforcement forensics and new drug development.
"We're able to give people an understanding of what regions of the world their genetic ancestors came from," said Mr. Gabriel. "We're working with the FBI to help identify serial killers and with Scotland Yard (where) there's a rapist in London who has been operating over 13 years. We also work in the area of pharmacogenomics, where understanding human genetic populations is important to understanding drug metabolism and also understanding disease."
When asked about criticism of the technology, including claims that DNA tests are too diluted to give an accurate ancestry picture, Mr. Gabriel responded: "It's such a new field. I liken it to discovering a continent. We don't know yet what the paths are. We don't know yet all of the secrets that are contained in the DNA. And I think it would be a mistake to restrict the exploration of this new continent by condemning or barring the use of this technology by anyone."
DNAPrint Genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (with end stage renal disease). Preclinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to design actual trials better and are targeted to patients with genetic profiles indicating their propensity to have the best clinical responses. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWITNESS(tm), RETINOME(tm), ANCESTRYbyDNA(tm) and EURO-DNA(tm). DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results.
Forward-Looking Statements
All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint Genomics, Inc. expressly disclaims any obligation or undertaking, except as may be required by applicable law or regulation to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.
CONTACT: DNAPrint Genomics, Inc. Richard Gabriel, CEO and President 941-366-3400
The Wall Street Group, Inc. Ron Stabiner 212-888-4848
-------------------- w i k i s t o c k . c o m Posts: 234 | From: Gainesville, FL | Registered: Feb 2005
| IP: Logged |
posted
This one is on the right track. Only a matter of time!
Updated:2006-05-09 07:25:07 DNAPrint Pharmaceuticals Selects GMP Manufacturer for PT-401 Anemia Drug Market Wire
SARASOTA, FL -- (MARKET WIRE) -- 05/09/06 -- DNAPrint Genomics, Inc. (OTC BB: DNAG) today announced that KBI BioPharma, Inc. has been selected as the Company's Good Manufacturing Practices (GMP) manufacturer of PT-401, a more powerful form of the anemia drug Erythropoietin (EPO).
"GMP manufacturing is the next step in our research and development of PT-401," stated DNAPrint Genomics President and Chief Executive Officer Richard Gabriel. "The GMP material produced by KBI BioPharma will be used to conduct preclinical studies required for a future Investigational New Drug Application, including toxicology studies and studies involving volunteers and patients."
"The development of PT-401 is an exciting project for our Company, based on the success of our initial work on this compound," said Dr. Hector J. Gomez, M.D., Ph.D., Chief Medical Officer and Chairman of DNAPrint.
DNAPrint Genomics obtained an exclusive, worldwide license from Harvard Medical School's Beth Israel Deaconess Medical Center in February 2005 for the development of a "Super" EPO, a more potent and longer acting form of Erythropoietin. The Company's goal is to utilize recent genomics and chemistry advances to develop next-generation test/drug combinations called "theranostics," designed to maximize efficacy and minimize side effects by tailoring and customizing medication for specific individuals and well-defined population sectors.
About KBI BioPharma, Inc.
KBI BioPharma, Inc., a leading contract process development and manufacturing service provider for the biopharmaceutical industry, accelerates and optimizes drug development and manufacturing programs. KBI BioPharma applies advanced biophysical and biochemical characterization techniques to develop scalable, robust processes resulting in products that exhibit optimal stability and biological activity. KBI BioPharma's scientific staff possesses the experience, including numerous IND and NDA submissions, to succeed in the challenges associated with all stages of drug development. KBI's services are performed in state-of-the-art laboratories housed in a 341,000 square foot facility in Durham, N.C. www.kbibiopharma.com.
About DNAPrint Genomics, Inc.
DNAPrint Genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (with end stage renal disease). Preclinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to design actual trials better and are targeted to patients with genetic profiles indicating their propensity to have the best clinical responses. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWITNESS(TM), RETINOME(TM), ANCESTRYbyDNA(TM) and EURO-DNA(TM). DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results.
-------------------- Veni Vidi Vici Posts: 529 | From: CA | Registered: Jan 2005
| IP: Logged |
Gamma Pharmaceuticals Signs Distribution Agreement and Accepts First Purchase Order for $1.03 Million Jan 21, 2010 9:49:00 AM Email Story Discuss on ZenoBank
View Additional Profiles
LAS VEGAS, NV -- (MARKET WIRE) -- 01/21/10 -- Gamma Pharmaceuticals Inc. (PINKSHEETS: GMPM) announced today that the Company has signed a Distribution Agreement for Gamma's branded product ranges. Under the Distribution Agreement, Gamma's monthly sales will ramp-up to $3.4 million. The first monthly purchase order has been accepted with a value of $1.03 million. The Agreement marks a significant milestone for Gamma, as it provides a key piece in the Company's North American Distribution plan. Gamma offers the industry's most distinctive blend of brands, product forms, marketing programs and market message all focused on moving products through large and profitable sales channels. The order received includes the Company's proprietary GELIbites®, GELIthins® and GELIcreams®. Peter Cunningham, Gamma CEO, commented, "We are very excited to have contracted with such a capable partner and are working diligently to piece together a distribution network that will drive high volume, high value sale for years to come. We feel that 2010 will be a game changer for Gamma in every respect as we deliver on our potential and drive shareholder value. We have a deep sales pipeline that we will fill in the weeks and months ahead."
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
